Autoresonance in a Dissipative System

We study the autoresonant solution of Duffing's equation in the presence of dissipation. This solution is proved to be an attracting set. We evaluate the maximal amplitude of the autoresonant solution and the time of transition from autoresonant growth of the amplitude to the mode of fast oscillations. Analytical results are illustrated by numerical simulations.Comment: 22 pages, 3 figure

DBR and DFB lasers in neodymium-and ytterbium-doped photothermorefractive glasses

The first demonstration, to the best of our knowledge, of distributed Bragg reflector (DBR) and monolithic distributed feedback (DFB) lasers in photothermorefractive glass doped with rare-earth ions is reported. The lasers were produced by incorporation of the volume Bragg gratings into the laser gain elements. The need for environment-insensitive, compact, robust, narrow line laser sources has stimulated the development of hybrid devices, such as distributed Bragg reflector (DBR) lasers, in which a laser resonator is produced by Bragg mirrors incorporated in a gain element, or distributed feedback (DFB) lasers, in which a resonator is produced by a Bragg grating that occupies the whole gain element. The concept of DFB was first successfully applied to optically pumped dye lasers The PTR glass has composition (M%) The two last elements are responsible for initiation of the photostructural transformations in the glass and enable VBG recording. As it was demonstrated in our earlier studies Nd-and Yb-doped PTR glasses with 2 wt. % of Yb and Nd ions have been prepared. The measurements of emission spectra were carried out in these glasses using an Ocean Optics spectrometer when glass samples were excited with a diode laser emitting at 808 nm (in the case of Nd ions) and 915 nm (for Yb ones

Search for Top Squark Pair Production in the Dielectron Channel

This report describes the first search for top squark pair production in the channel stop_1 stopbar_1 -> b bbar chargino_1 chargino_1 -> ee+jets+MEt using 74.9 +- 8.9 pb^-1 of data collected using the D0 detector. A 95% confidence level upper limit on sigma*B is presented. The limit is above the theoretical expectation for sigma*B for this process, but does show the sensitivity of the current D0 data set to a particular topology for new physics.Comment: Five pages, including three figures, submitted to PRD Brief Report

ЭКОНОМИЧЕСКОЕ ОБОСНОВАНИЕ ПРИМЕНЕНИЯ НОВЫХ СХЕМ ХИМИОТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ С ШИРОКОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТЬЮ

The article presents economic feasibility evaluation for using high-priced drugs in the regimens for treatment of tuberculosis patients with extensive drug resistance.Subjects and Methods. Treatment efficiency was evaluated in 175 tuberculosis patients with extensive drug resistance, treated by four different regimens, including third line drugs and without them; the economic impact of each regimen was evaluated. Two types of pharmaco-economic analysis were used: costs – effectiveness and budget impact analysis.Results of the study. Despite the significant costs of regimens containing moxifloxacin, linezolid, and bedaquiline, the co-efficient of costs – effectiveness turned out to be the lowest. When using models for comparing costs and losses over 5 year period of XDR TB patients treatment it was found out that regimens containing moxifloxacin, linezolid and bedaquiline possessed significant economic predominance which required major investment at the initial stages of introduction, and by the end providing savings from 46.3 to 65.3% of the budget compared to the regimens without these drugs. The obtained results provide the evidence that use of regimens containing new highly effective drugs (moxifloxacin, linezolid and bedaquiline) in rational combinations with basic and reserve drugs, prescribed with consideration of drug resistance profile allow achieving the significant economic effect. Проведена оценка экономической целесообразности применения дорогостоящих препаратов в схемах лечения больных туберкулезом легких с широкой лекарственной устойчивостью.Материалы и методы. На основе исследования эффективности лечения 175 больных туберкулезом с широкой лекарственной устойчивостью (ШЛУ-ТБ) четырьмя различными схемами химиотерапии, с включением препаратов третьего ряда и без такового, исследован экономический эффект каждой схемы. Использовано два вида фармакоэкономического анализа «затраты – эффективность» и анализ «влияния на бюджет» (Budget impact analysis).Результат исследования. Несмотря на большие экономические затраты на схемы химиотерапии с включением моксифлоксацина, линезолида и бедаквилина, коэффициент «затраты – эффективность» оказался наименьшим. При сравнении на моделях финансовых затрат и потерь за пятилетний период лечения больных ШЛУ-ТБ установлено, что значительное экономическое превосходство имеют схемы химиотерапии с включением моксифлоксацина, линезолида и бедаквилина, требующие значительных инвестиций на начальных этапах внедрения, при этом позволяющие получить к концу периода экономию от 46,3 до 65,3% бюджета в сравнении с применением схемы химиотерапии без данных препаратов. Полученный результат свидетельствует, что применение схем химиотерапии, содержащих новые высокоэффективные препараты (моксифлоксацин, линизолид и бедаквилин) в рациональных комбинациях с другими препаратами основного и резервного рядов, подобранных с учетом лекарственной устойчивости возбудителя, сопряжено с выраженным экономическим эффектом.

ЭКОНОМИЧЕСКОЕ ОБОСНОВАНИЕ ПРИМЕНЕНИЯ НОВЫХ СХЕМ ХИМИОТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ С ШИРОКОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТЬЮ

The article presents economic feasibility evaluation for using high-priced drugs in the regimens for treatment of tuberculosis patients with extensive drug resistance.Subjects and Methods. Treatment efficiency was evaluated in 175 tuberculosis patients with extensive drug resistance, treated by four different regimens, including third line drugs and without them; the economic impact of each regimen was evaluated. Two types of pharmaco-economic analysis were used: costs – effectiveness and budget impact analysis.Results of the study. Despite the significant costs of regimens containing moxifloxacin, linezolid, and bedaquiline, the co-efficient of costs – effectiveness turned out to be the lowest. When using models for comparing costs and losses over 5 year period of XDR TB patients treatment it was found out that regimens containing moxifloxacin, linezolid and bedaquiline possessed significant economic predominance which required major investment at the initial stages of introduction, and by the end providing savings from 46.3 to 65.3% of the budget compared to the regimens without these drugs. The obtained results provide the evidence that use of regimens containing new highly effective drugs (moxifloxacin, linezolid and bedaquiline) in rational combinations with basic and reserve drugs, prescribed with consideration of drug resistance profile allow achieving the significant economic effect. Проведена оценка экономической целесообразности применения дорогостоящих препаратов в схемах лечения больных туберкулезом легких с широкой лекарственной устойчивостью.Материалы и методы. На основе исследования эффективности лечения 175 больных туберкулезом с широкой лекарственной устойчивостью (ШЛУ-ТБ) четырьмя различными схемами химиотерапии, с включением препаратов третьего ряда и без такового, исследован экономический эффект каждой схемы. Использовано два вида фармакоэкономического анализа «затраты – эффективность» и анализ «влияния на бюджет» (Budget impact analysis).Результат исследования. Несмотря на большие экономические затраты на схемы химиотерапии с включением моксифлоксацина, линезолида и бедаквилина, коэффициент «затраты – эффективность» оказался наименьшим. При сравнении на моделях финансовых затрат и потерь за пятилетний период лечения больных ШЛУ-ТБ установлено, что значительное экономическое превосходство имеют схемы химиотерапии с включением моксифлоксацина, линезолида и бедаквилина, требующие значительных инвестиций на начальных этапах внедрения, при этом позволяющие получить к концу периода экономию от 46,3 до 65,3% бюджета в сравнении с применением схемы химиотерапии без данных препаратов. Полученный результат свидетельствует, что применение схем химиотерапии, содержащих новые высокоэффективные препараты (моксифлоксацин, линизолид и бедаквилин) в рациональных комбинациях с другими препаратами основного и резервного рядов, подобранных с учетом лекарственной устойчивости возбудителя, сопряжено с выраженным экономическим эффектом.

Measurement of the WW Boson Mass

A measurement of the mass of the $W$ boson is presented based on a sample of 5982 $W \rightarrow e \nu$ decays observed in $p\overline{p}$ collisions at $\sqrt{s}$ = 1.8~TeV with the D\O\ detector during the 1992--1993 run. From a fit to the transverse mass spectrum, combined with measurements of the $Z$ boson mass, the $W$ boson mass is measured to be $M_W = 80.350 \pm 0.140 (stat.) \pm 0.165 (syst.) \pm 0.160 (scale) GeV/c^2$.Comment: 12 pages, LaTex, style Revtex, including 3 postscript figures (submitted to PRL

Search for W~1Z~2\widetilde{W}_1\widetilde{Z}_2 Production via Trilepton Final States in ppˉp\bar{p} collisions at s=1.8\sqrt{s}=1.8 TeV

We have searched for associated production of the lightest chargino, $\widetilde{W}_1$, and next-to-lightest neutralino, $\widetilde{Z}_2$, of the Minimal Supersymmetric Standard Model in $p\bar{p}$ collisions at \mbox{$\sqrt{s}$ = 1.8 TeV} using the \D0 detector at the Fermilab Tevatron collider. Data corresponding to an integrated luminosity of 12.5$\pm 0.7$ \ipb were examined for events containing three isolated leptons. No evidence for $\widetilde{W}_1\widetilde{Z}_2$ pair production was found. Limits on $\sigma(\widetilde{W}_1\widetilde{Z}_2)$Br$(\widetilde{W}_1\to l\nu\widetilde{Z}_1)$Br$(\widetilde{Z}_2\to l\bar{l}\widetilde{Z}_1)$ are presented.Comment: 17 pages (13 + 1 page table + 3 pages figures). 3 PostScript figures will follow in a UUEncoded, gzip'd, tar file. Text in LaTex format. Submitted to Physical Review Letters. Replace comments - Had to resumbmit version with EPSF directive